Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drotaverine hydrochloride versus hyoscine butylbromide for reducing the first stage of labour among nulliparous women
PACTR202206902932545Completed
- Sponsor
- Nnenna S Nweke
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of drotaverine, hyoscine butylbromide and Compound Vitamin B (3 arms), sponsored by Nnenna S Nweke. Primary endpoint: Efficacy in reducing duration of first stage of labour. Started May 2019; status: completed.
02
Drugs
drotaverinehyoscine butylbromideCompound Vitamin B
Beyond the preview
Go deeper on PACTR202206902932545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202206902932545.